Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.57 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.53 |
| ▸ | BID | P55957 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.52 |
| ▸ | ECE1 | P42892 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604887 | 1.00 | MC4R (0.57) | MC4RACEKMT2AALOX15BCL2A1 | |
| SCHEMBL28235858 | 0.96 | ACE (0.57) | MC4RACEKMT2AALOX15ECE1 | |
| SCHEMBL29419957 | 0.94 | MC4R (0.63) | MC4RKISS1R | |
| SCHEMBL28058268 | 0.94 | MC4R (0.60) | MC4RKMT2ABCL2A1BIDKISS1R | |
| SCHEMBL28058267 | 0.94 | MC4R (0.60) | MC4RKMT2ABCL2A1BIDKISS1R | |
| SCHEMBL19444259 | 0.92 | MC4R (0.56) | MC4RKMT2ABCL2A1BIDKISS1R | |
| SCHEMBL13599545 | 0.92 | MC4R (0.56) | MC4RKMT2ABCL2A1BIDKISS1R | |
| SCHEMBL30325341 | 0.92 | GHSR (0.59) | ACEKISS1RECE1 | |
| SCHEMBL13599541 | 0.91 | MC4R (0.56) | MC4RKMT2ABCL2A1BID | |
| SCHEMBL30200105 | 0.91 | ACE (0.52) | ACEKMT2AKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | MC4R 1/4885ACE 2940/4885KMT2A 440/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | MC4R 1/4885ACE 1785/4885KMT2A 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.